Regenerative Medical Technology (RMTG) Gross Profit (2018 - 2026)

Regenerative Medical Technology's Gross Profit history runs 9 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• In Q1 2026, Gross Profit rose 87.15% year-over-year to $1.8 million; the TTM figure through Mar 2026 stood at $3.6 million (up 13.61% YoY), while the FY2025 annual figure was $2.8 million, changed 0.44% from the prior year.
• Gross Profit for Q1 2026 stood at $1.8 million, up from $779495.0 in the prior quarter.
• The five-year high for Gross Profit was $1.8 million in Q1 2026, with the low at $106264.0 in Q1 2022.
• The 5-year median for Gross Profit is $526884.0 (2024), against an average of $585471.9.
• The sharpest annual moves came in 2022 and 2025: Gross Profit soared 3659.79% in 2022, then plunged 32.86% in 2025.
• Regenerative Medical Technology's Gross Profit stood at $358814.0 in 2022, then increased by 21.16% to $434750.0 in 2023, then jumped by 125.46% to $980183.0 in 2024, then decreased by 20.47% to $779495.0 in 2025, then surged by 126.62% to $1.8 million in 2026.
• Business Quant data shows RMTG's Gross Profit at $1.8 million in Q1 2026, $779495.0 in Q4 2025, and $501557.0 in Q3 2025.